Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study-Reference-Cited by-同舟云学术

Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study

Published:2010-03-18 Issue:1 Volume:10 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Joly-Guillou Marie-Laure,Kempf Marie,Cavallo Jean-Didier,Chomarat Monique,Dubreuil Luc,Maugein Jeanne,Muller-Serieys Claudette,Roussel-Delvallez Micheline

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/article/10.1186/1471-2334-10-72/fulltext.html

Reference26 articles.

1. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA: Comparative review of the carbapenems. Drugs. 2007, 67: 1027-1052. 10.2165/00003495-200767070-00006.

2. Jones RN, Mendes C, Turner PJ, Masterton R: An overview of the meropenem yearly susceptibility test information collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis. 2005, 53: 247-256. 10.1016/j.diagmicrobio.2005.10.006.

3. Unal S, Garcia-Rodriguez JA: Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. Isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis. 2005, 53: 265-271. 10.1016/j.diagmicrobio.2005.10.002.

4. Masterton RG, Turner PJ: Trends in antimicrobial susceptibility in UK centres: the MYSTIC programme (1997-2002). Int J Antimicrob Agents. 2006, 27: 69-72. 10.1016/j.ijantimicag.2005.09.011.

5. Turner PJ: Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program. Diagn Microbiol Infect Dis. 2006, 56: 341-344. 10.1016/j.diagmicrobio.2006.07.015.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal use of β-lactams in neonates: machine learning-based clinical decision support system;eBioMedicine;2024-07

2. Prevalence and antimicrobial resistance of uropathogens in Karachi, Pakistan;Acta Biologica Szegediensis;2023-12-15

3. The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock;Heliyon;2023-06

4. Salvia sclarea Essential Oil Chemical Composition and Biological Activities;International Journal of Molecular Sciences;2023-03-08

5. Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?;Antibiotics;2023-02-13